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Abstract
Objectives To assess the presence of symptoms consistent with 
Attention Deficit Disorder with Hyperactivity (ADHD) in all patients 
with early-treated phenylketonuria (PKU) in the State of Santa 
Catarina in southern Brazil.
Materials & Methods 
All of the patients diagnosed with PKU by newborn-screening tests, 
with ages varying from 6 to 18 years and who started treatment before 
60 days of life and presented phenylalanine levels consistently below 
6 mg/dL throughout treatment, were included. The subjects were 
invited to complete a questionnaire that collected sociodemographic, 
gestational and clinical data. ADHD symptoms were assessed using 
the revision of the Swanson, Nolan and Pelham Questionnaire.
Results
A total of 34 patients were evaluated, who were 53% male and 94% 
white and had an average age of 12 years, and 15% were born premature. 
According to the Swanson, Nolan and Pelham Questionnaire, 13 patients 
(38%) met the diagnostic criteria for ADHD, with 2 patients having the 
inattentive type, 6 patients having the hyperactive or impulsive type 
and 1 patient having the oppositional defiant disorder type.
Conclusion
Although the patients with PKU were regularly treated from birth, 
there was a high prevalence of symptoms consistent with ADHD. A 
pathophysiological interface that involves the dopamine metabolic 
pathway may exist between the two conditions.
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Introduction
Phenylketonuria (PKU) is a genetic disorder 
that involves the ineffective conversion of Phe 
(phenylalanine) into tyrosine and consequently 
causes a deficit in the production of precursors, 
one of which is dopamine (DA) (1-6). 
Neurobiologically, Attention Deficit Disorder 
with Hyperactivity (ADHD) appears to be closely 
related to the dopaminergic neurotransmission 
system. DA is a neurotransmitter that has a key role 
in attention and concentration. Moreover, cortical 
dopaminergic pathways act in mediating cognitive 
functions, such as learning, maintaining attention 
and concentration (3,4). Individuals with PKU and 
ADHD seem to have low levels of DA in common, 
causing the hypodopaminergic state found in both 
disorders to be a possible link between these two 
conditions, and individuals with PKU could have 
a greater predisposition to the development of 
ADHD.
The prefrontal cortex is especially sensitive to 
low levels of DA, and it is speculated that even 
moderate elevations of Phe may result in low 
levels of DA in the central nervous system. ADHD 
and PKU are therefore theoretically linked by low 
levels of available DA in the prefrontal cortex (7-
9). Many authors have questioned the existence of 
a pathophysiological relationship between PKU 
and ADHD and emphasize the importance of 
additional studies that may further elucidate the 
relationship between these entities (10). Despite 
the existence of theoretical background, there are 
few reports studying the linkage between ADHD 
and PKU. The aim of this study was to verify the 
presence of ADHD symptoms in patients with 
early-treated PKU. 
Materials & Methods
A cross-sectional study assessing ADHD 
symptoms in every early-treated PKU patient 
living in the State of Santa Catarina was conducted 
in 2012. The study was performed at the Hospital 
Infantil Joana de Gusmão, the largest pediatric 
hospital in the State of Santa Catarina. Located at 
Florianópolis, the capital city of Santa Catarina, 
the Hospital Infantil Joana de Gusmão is a tertiary 
center for metabolic disorders. Every case of PKU 
detected by newborn-screening tests is referred to 
this hospital.
Patients
Every PKU patient diagnosed by a neonatal-
screening test in the State of Santa Catarina was 
enrolled in this study. Of those patients, every 
individual between 6 and 18 years old who 
was regularly treated since birth, according to 
the “Brazilian Phenylketonuria Clinical and 
Therapeutic Guidelines”, was included in this 
study (11). 
Every PKU patient who started treatment after 
60 days of age, who failed to maintain Phe levels 
below 6 mg/dL or who failed to adhere to regular 
medical follow-ups were excluded.
Procedures
During regular medical appointments, the patients’ 
legal representatives, who were usually the patients’ 
parents, were asked to complete questionnaires 
regarding epidemiological data (age, gender, 
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income and educational degree), clinical data 
(familial consanguinity, pregnancy and birth) and 
ADHD symptoms. The Portuguese version of 
the “Swanson, Nolan and Pelham Questionnaire 
(SNAP-IV)” was used (12).
ADHD
The diagnosis of ADHD is essentially clinical, 
based on clear and well-defined operational 
criteria derived from classification systems such 
as the Diagnostic and Statistical Manual of Mental 
Disorders , Fourth Edition (DSM-IV) (13).
According to the DSM-IV, for the diagnosis of 
ADHD, it is essential to identify the presence of 
symptoms consistent with ADHD that present 
before the age of 7 in at least two different contexts 
(e.g., at home and at school) and are associated 
with evident damage in school, social or family 
life and to determine whether those existing 
symptoms are not better explained by the presence 
of another psychiatric disorder. A confirmation of 
the diagnosis can only be achieved through proper 
neurological or psychiatric investigation (14).
In this study, the Portuguese version SNAP-IV was 
used for the standardization of ADHD symptoms 
(12).
The SNAP-IV is a questionnaire containing 26 
items aimed at parents and teachers and related 
to ADHD symptoms. The items are subdivided 
into scales related to the symptoms of inattention 
(items 1 to 9), hyperactivity or impulsivity (items 
10 to 18) and oppositional defiant disorder (ODD; 
19 to 26). Each question about a symptom can be 
answered in four different ways: “not at all”, “just 
a little”, “quite a bit” or “very much”. Only the 
presence of six or more responses of “quite a bit” 
or “very much” on the items related to inattention 
and/or hyperactivity indicate the presence of 
ADHD symptoms (12).
When there are at least six items marked as 
“quite a bit” or “very much” among items 1 to 
9 of the SNAP-IV, there are more symptoms of 
inattention than expected in a child or adolescent, 
and the individual has symptoms suggestive of the 
inattentive subtype of ADHD (12,15).
If there are at least six items marked as “quite a 
bit” or “very much” among items 10 to 18 of 
the SNAP-IV, then there are more symptoms of 
hyperactivity or impulsivity than expected in a 
child or adolescent, thus identifying the hyperactive 
or impulsive subtype of ADHD (12,15,16).
We included items related to the DSM-IV criteria 
for ODD, corresponding to items 19 to 26 of the 
SNAP-IV, because ODD increases the risk of the 
emergence of antisocial behavior in children and 
adolescents and is often present in those individuals 
with ADHD (12).
Statistical Analysis
Statistical analysis was performed using EpiInfo 
version 3.5.3 for Windows.
Results are presented as absolute and relative 
frequencies for qualitative variables and as the 
mean value and standard deviation for quantitative 
variables. Differences in proportions were assessed 
by a chi-square or Fisher’s exact test, with a 
significance level of 5%. A possible association 
between risk factors and ADHD was verified by the 
prevalence ratio (PR), with a confidence interval 
(CI) of 95%. 
Results
In 2012, the State of Santa Catarina had a total of 
142 patients with a confirmed diagnosis of PKU, 
of which 77 were diagnosed and treated from birth. 
Among those individuals, a total of 34 patients 
were considered to be eligible for our study.
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Sociodemographic and Epidemiological Aspects
Regarding the city of birth, there is a homogeneous 
distribution across the State of Santa Catarina, with 
the 34 PKU patients spread across all regions of 
the state, as observed in detail in Figure 1.
Regarding the epidemiological variables, as shown 
in Table 1, there was a slight predominance of men 
(53%) and white patients (94%) in the sample. 
The mean age was 12 years. Considering children 
who were 12 years old or less and adolescents who 
were older than 12 years old, our sample consisted 
of 19 children (56%) and 15 adolescents (44%). 
Regarding family income, we observed that most 
parents of PKU patients earned up to five times the 
minimum wage.
It was observed that only 2 patients had a history 
of parental consanguinity. In one case, the parents 
were cousins  , and in another, the parents were 
an uncle and n iece. Most patients were born by 
cesarean deli v ery and at term. Most patients 
received regular treatment, consisting of a specific 
diet for PKU (foods with Phe restriction) and using 
special protein formulas (with Phe restriction). A 
minority of patients only received dietary treatment 
but still managed to successfully keep their blood 
Phe levels below 6 mg/dL (Table 1).
Education Level
Regarding the education of the PKU patients, 26 
patients (76% )  were up-to-date with their age-
appropriate class, without grade repetition. 
Concerning the higher parents’ education, half of 
the parents had a complete or incomplete university 
education (Table 2).
ADHD
Taking into account the criteria for clinical 
symptoms suggestive of ADHD, i.e., considering 
six or more answers of “quite a bit” or “very much” 
on the SNAP-IV questionnaire as positive for 
ADHD, 13 patients (38%) in our sample showed 
symptoms suggestive of ADHD.
Among the patients with symptoms suggestive of 
ADHD, 2 patients (15%) could be classified as 
having the inattentive subtype of ADHD, whereas 
6 patients (46%) could be classified as having the 
hyperactive or impulsive ADHD subtype according 
to the SNAP-IV. Only 1 patient fit the ODD criteria 
and also showed symptoms suggestive of ADHD.
A statistical comparison of the data can be viewed 
in detail in Table 3. When comparing the prevalence 
of symptoms suggestive of ADHD in relation 
to gender, we found that  6 patients (46%) were 
female, whereas 7 patients (54%) were male. There 
was no statistical significant relationship between 
sex and the prevalence of positive symptoms of 
ADHD. 
Considering prematurity and positive ADHD 
symptoms, 2 patients (15%) were premature, 
whereas 11 patients (85%) were born at term. 
Thus, in this case, prematurity was not related to 
the increased presence of symptoms suggestive of 
ADHD (Table 3).
Regarding parental consanguinity and positive 
symptoms of ADHD, we found that all patients 
with consanguineous parents (n=2) had symptoms 
consistent with ADHD. Of the 32 patients whose 
parents were not consanguineous, 11 subjects (34%) 
had symptoms consistent with ADHD. When the 
PR between symptoms consistent with ADHD and 
the presence or absence of consanguineous parents 
was calculated, it was observed that the prevalence 
of ADHD symptoms was approximately three 
times higher in patients with consanguineous 
parents than in patients without consanguinity (PR 
= 2.9, 95% CI 1.8 to 4.7, Table 3).
Regarding the type of delivery, 5 patients (38%) 
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with symptoms suggestive of ADHD were born 
vaginally, and 8 (62%) were born through a 
cesarean. The ADHD diagnosis prevalence rate 
of those individuals who underwent a normal 
birth compared with those patients who were born 
through a cesarean delivery was 1.14 (95% CI 0.48 
to 2.73), and there was no statistical significant 
association between the type of delivery and 
ADHD diagnosis (Table 3).
Figure 1 - Distribution of patients with phenylketonuria treated early in the State of 
Santa Catarina according to the city of birth (n=34). 
Figure 1: Distribution of patients with phenylketonuria treated early in the State of Santa Catarina according to the city of birth (n=34).
 Adapted from “Guia Turístico e Cultural do Estado de Santa Catarina”. Web site: http://www.sctur.com.br/
images/mapa_sc_2008g.jpg. Acessed in March 14, 2013.
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aA premature baby was considered to be a baby born before 37 complete weeks of gestation.
bIncome is expressed in minimum wages, for which one wage corresponds to 622 BRL ($315.73 as of 03/15/2013).




























Table 3: Relationship between characteristics in patients with phenylketonuria and symptoms suggestive of Attention Deficit Disorder 
with Hyperactivity (n=13).






Premature 2 15 0.64b
Term 11 85
Parental consanguinity
Yes 2 15 0.13b
No 11 85
Childbirth
Normal/vaginal 5 38 0.52b
Cesarean 8 62
aChi-square test, significance level of 5%.
bFisher’s exact test, significance level of 5%.
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Discussion
Individuals with PKU and ADHD seem to 
have low levels of DA in common, causing the 
hypodopaminergic state found in both disorders to 
be a possible link between these two conditions, 
and individuals with PKU could have a greater 
predisposition to the development of ADHD.
For the first time in Brazil, this study assessed 
the relationship between PKU, a rare genetic and 
neurometabolic disease, with ADHD, the most 
common neurobehavioral condition affecting the 
pediatric population. We believe that these two 
conditions can be comorbid.
The term “comorbidity” was initially described by 
Feinstein to describe the association of two morbid 
conditions in the same person (17). More recently, 
this term has been used with a more restricted 
meaning, referring to the non-random association 
of two or more morbid conditions in a single 
individual (18).
The proper study of comorbid conditions is of 
extreme importance to several aspects, yielding 
implications for the correct diagnosis of both 
conditions, allowing the creation of new therapeutic 
opportunities and possibly providing clues to 
understanding the pathophysiology of diseases.
The present study also allowed the study of a 
highly specific population: patients with PKU 
diagnosed from birth who started treatment early 
and, most importantly, are continuing to receive 
proper treatment.
In our study, we found the presence of symptoms 
consistent with ADHD in 13 patients (38.2%), 
most of whom were classified as having the 
hyperactive or impulsive subtype of ADHD. This 
prevalence is much higher than the prevalence 
verified in previous studies: 4 to 12% with ADHD 
in the general pediatric population of 6 to 12 years 
old (8,19). In Brazil, Vasconcelos MM et al., who 
evaluated children between 6 and 15 years old, 
found a 17.1% prevalence of ADHD, mostly of the 
inattentive subtype (20).
A significant percentage of our sample lost at least 
1 year in schooling. Antshel KM et al. claim that 
academic difficulties are relatively common in 
children and adolescents with PKU and may be a 
function of ADHD, executive function deficits or 
deficits in processing speed (4). Moreover, the high 
prevalence of symptoms consistent with ADHD 
found in our sample of PKU patients suggests a 
link to the high repetition rate that we found. In 
a meta-analysis, Frazier TW et al. reported the 
average difference in academic performance 
between ADHD and control groups, by showing 
that young people with ADHD have a higher risk 
of failure and abandoning school (21). Authors 
stressed that so far, no data have been reported 
on the association between ADHD and school 
outcomes in the PKU population (22).
Certain studies observed an association between 
the PKU and TDAH. A study by Antshel KM et 
al. examined a sample of 46 children with classical 
PKU (mean age: 10.8 years), several of these 
individuals began treatment late and thus were 
exposed to high levels of Phe. Using strict DSM-
IV criteria, 6 children (13%) met the full criteria 
for ADHD, with a prevalence that was 2.5 times 
higher than in the general population in this study. 
All children were diagnosed with ADHD of the 
inattentive type. The results indicated that high 
levels of Phe are toxic to the neurological system 
that manages the executive and cognitive functions 
and that the duration of exposure to high levels of 
Phe can affect the expression of ADHD symptoms 
(23,24).
As in the current study, other authors have 
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demonstrated an indirect association between PKU 
and attention disorders, as demonstrated by Arnold 
GL et al., who evaluated the prevalence of stimulant 
medication use by reviewing the medical records 
of a sample of 38 young people with classical 
PKU treated early and continuously (mean age: 
11 years) (22). In total, 19 of the parents of the 
young people with PKU (50%) reported that their 
child had significant symptoms of inattention. For 
10 children, a stimulant medication for attentional 
dysfunction was prescribed, which, according 
to parental report, was effective. Furthermore, a 
significant relationship was found between high 
levels of Phe with symptoms of inattention and the 
increased use of stimulants (22).
Nothing has been found in the literature that is 
similar to the results of our study, in which only 
patients treated properly and early for PKU were 
selected and in which PKU’s association with 
ADHD was observed. Many authors emphasize 
the need for studies to more clearly and explicitly 
demonstrate the relationship between PKU 
and ADHD (16,23). This study demonstrated a 
possible relationship between these two entities, 
reinforcing the theory that the hypodopaminergic 
state found in patients with PKU may contribute to 
the development of ADHD.
ADHD is a multifactorial condition with risk 
factors with genetic and environmental aspects 
(20). The influence of environmental factors is 
highly accepted in the literature, and especially 
the relationship with premature birth and low 
parental education (25). In our study, patients with 
symptoms consistent with ADHD were mostly 
born at term, and the patients’ parents had higher 
education in 50% of cases. Thus, we speculate that 
ADHD symptoms may be nearly entirely related 
to PKU.
A literature review conducted by Brumm VL et 
al. on psychological and psychiatric disorders 
and PKU reveals that the prevalence and severity 
of these problems are correlated with the time 
and degree of exposure to elevated Phe levels 
in the blood (26). Children with poor metabolic 
control and those individuals with a late initiation 
of treatment are more likely to be affected 
and have more severe symptoms. The authors 
report that individuals with PKU, even if treated 
continuously, have an increased risk of presenting 
symptoms of inattention and distraction (26). The 
current literature mostly emphasizes that most 
neurobehavioral symptoms found in patients 
with PKU who are diagnosed and treated early 
may be related to poor adherence to treatment or 
fluctuations in Phe levels throughout life (3).
In our study, however, we evaluated only patients 
diagnosed and treated early who undergo regular 
medical monitoring and always maintain their Phe 
levels as recommended. Thus, we suggest that 
the neurobehavioral symptoms cannot be fully 
explained by a failure in therapy. R Sharman et al. 
support this concept, suggesting that monitoring 
the levels of tyrosine, an important metabolite 
of the DA synthesis pathway, and its eventual 
replacement must be added to the therapeutic 
armamentarium of PKU (27).
In our study, certain limitations can be observed. It 
should be noted that other criteria are also needed 
for the diagnosis of ADHD. The SNAP-IV criteria 
must be accompanied by a neuropsychological 
evaluation of these patients, and other tests may 
be used to assist in diagnosis. To develop a more 
precise diagnosis, an investigation of the story of a 
child’s life is always appropriate for contextualizing 
symptoms.
In addition, because PKU is a rare condition, 
101
Attention Deficit Disorder with Hyperactivity Symptoms in Early-Treated Phenylketonuria Patients
Iran J Child Neurol. winter 2020 Vol. 14 No. 1
although we evaluated all patients in the State of 
Santa Catarina, we analyzed a relatively small 
population, preventing a more appropriate analysis 
of the data. Regarding the type of study, the 
impossibility of inferring causality from the studied 
factors from a cross sectional study is emphasized.
In Conclusion, Our study reinforced the theory 
that the hypodopaminergic state found in patients 
with PKU, although appropriately treated, may 
contribute to the development of other conduct 
disorders, and particularly ADHD. Although 
patients are regularly treated from birth, PKU can 
be an important risk factor for the development of 
ADHD. Studies such as this one suggest an interface 
between the two pathophysiological conditions 
that involves dopamine metabolism. It is of great 
importance that professionals who manage PKU 
patients are aware of all of the neuropsychological 
symptoms that an individual might present to 
ensure more effective therapy.
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